Jpmorgan Chase & CO Surface Oncology, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.62 - $1.21 $1,457 - $2,844	-2,351 Reduced 62.56%	1,407 $1,000
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.1 $2,544 - $5,088	2,423 Added 181.5%	3,758 $4,000
Q2 2022 Aug 11, 2022	SELL	$1.42 - $3.15 $29,460 - $65,353	-20,747 Reduced 93.95%	1,335 $2,000
Q1 2022 May 11, 2022	BUY	$2.65 - $5.08 $12,219 - $23,423	4,611 Added 26.39%	22,082 $65,000
Q4 2021 Feb 10, 2022	BUY	$4.73 - $7.9 $2,828 - $4,724	598 Added 3.54%	17,471 $84,000
Q3 2021 Nov 12, 2021	BUY	$5.16 - $7.98 $87,064 - $134,646	16,873 New	16,873 $128,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.